Prakt. Lékáren. 2015; 11(3e) [Klin Farmakol Farm. 2014;28(3):112-116]

Drug-induced peripheral neuropathies

Štefan Alušík1, Zoltán Paluch2, 3
1 Institut postgraduálního vzdělávání ve zdravotnictví, Praha
2 Farmakologický ústav 1. lékařské fakulty Univerzity Karlovy, Oddělení klinické farmakologie, Všeobecná fakultní nemocnice, Praha
3 Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety v Bratislave, Ústav sv. Jana N. Neumanna, Příbram

The paper examines drugs of individual drug classes that are most likely to cause peripheral nerve injury. The authors describe theclinical features of injury in individual drugs as well as discuss the mechanism of injury, predisposing factors, relation to dose andcumulative dose, reversibility, and importance of early recognition of nerve injury. They suggest that drug-induced neuropathies aremore frequent than currently believed.

Keywords: peripheral neuropathies, drugs, vaccines

Published: August 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alušík Š, Paluch Z. Drug-induced peripheral neuropathies. Praktické lékárenství. 2015;11(E-verze 3/15):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ehler E. Polyneuropatie - klasifikace, diagnostika, terapie. Practicus 2012; 8: 17-21.
    2. Rutkove SB. Overview of polyneuropathy. (updated VI 3, 2013) http://www.uptodate.com/contens/overview-of-polyneuropathy.
    3. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997; 62: 310-318. Go to original source... Go to PubMed...
    4. Hughes RA. Peripheral neuropathy. BMJ 2002; 324: 466-469. Go to original source... Go to PubMed...
    5. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522. Go to original source...
    6. Jain KK. Drug induced peripheral neuropathies. In: Jain KK ed. Drug-induced Neurological Disorders. 2nd ed. Seattle: Hogrefe & Huber. 2001: 263-294.
    7. Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003; 3: 86-92. Go to original source... Go to PubMed...
    8. Weimer LH. Drug-induced neuropathies (last updated February 2, 2013). http://www.medlink.com/CIP.ASP?UID=MLT000M4.
    9. Hur J, Guo AY, Loh WY, Feldman EL, Bai JPF. Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. CPT Pharmacometrics Syst. Pharmacol 2014; 3,e114; doi: 10.1038/psp.2014.11. Go to original source...
    10. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: diagnosis and management. Am Fam Physician 2010; 81: 887-892. Go to PubMed...
    11. Anonymous. Drug-induced peripheral neuropathies. Prescrire Int 2013; 22: 208-212. Go to PubMed...
    12. Laedermann CJ, Cachemaille M, Kirschmann G, et al. Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain. J Clin Invest 2013; 123: 3002-3013. Go to original source... Go to PubMed...
    13. Zhao X, Tang Z, Zhang H, et al. A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nat Neurosci 2013; 16: 1024-1031. Go to original source... Go to PubMed...
    14. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced neuropathy. Toxicology 2012; 291: 1-9. Go to original source...
    15. Hesselink JMK. Editorial view-Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia-modulator. http://www.apicareonline.com/? p=881.
    16. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering citokines as targets for chemotherapy-induced peripheral neuropathy. Cytokine 2012; 59: 3-9. Go to original source... Go to PubMed...
    17. Smith EML, Pang H, Cirincione C, et al. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy-A Randomized Clinical Trial. JAMA 2013; 309: 1359-1367. Go to original source...
    18. Chang H. Drug-induced peripheral neuropathy in multiple myeloma patients-part 1: What is it and who is at risk? http://www.myelomabeacon.com/news/2012/03/26/drug-induced-peripheral-neuropath.
    19. Chang H. Drug-induced peripheral neuropathy in multiple myeloma patients-part 2: Treatment. http://www.myelomabeacon.com/news/2012/03/30/drug-induced-peripheral-neuropat.
    20. Cobleigh M. Once-weekly Velcade is equally effective but better tolerated in elderly multiple myeloma. http://myelomabeacon.com/news/2010/09/28/once-weekly-velcade-is-equally-effective-but-better-tolerated-in-elderly-multiple-myeloma-patients/.
    21. Chang H, Shilane J. Subcutaneous Velcade: Information for multiple myeloma patients. http://www.myelomabeacon.com/news/2011/09/02/subcutaneous-velcade-bortezomib.
    22. Anonymous. Bortézomib et neuropathies périphériques. Rev Prescrire 2009; 29: 266-267.
    23. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66: 218-228. Go to original source... Go to PubMed...
    24. Anonymous. Syndromes douloureux aigus sous paclitaxel. Rev Prescrire 2012; 32: 357-358.
    25. Osmani K, Vignes S, Aissi M, Wade F, Milani P, Lévy BI, et al. Taxane-induced peripheral neuropathy has good long-term prognosis. J Neurol. 2012; 259: 1936-1943. Go to original source... Go to PubMed...
    26. Schneider BP, Zhao F, Wang M, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012; 30: 3051-3057. Go to original source... Go to PubMed...
    27. Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012; 18: 5099-5109. Go to original source... Go to PubMed...
    28. Anonymous. Eribulin. Heavilly pretreated breast cancer: uncertain advantages, excesive adverse effects. Prescrire Int 2012; 21: 37-39. Go to PubMed...
    29. Higby DJ, Wallace HJ jr, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I. study showing responses in testicular and others tumors. Cancer 1974; 33: 1219-1225. Go to original source...
    30. Van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, Houwelingen JC, Nejit JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697-1702. Go to original source... Go to PubMed...
    31. Gregg RW, Molepo JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relation between dosage, time and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803. Go to original source...
    32. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011; 2011: 843019, doi: 10.1155/2011/843019. Go to original source...
    33. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-244. Go to original source... Go to PubMed...
    34. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy: clinical and electrophysiological observations. Brain 1973; 96: 69-86. Go to original source... Go to PubMed...
    35. Rowinsky E. The Vinca Alkaloids. In: Kufe DW, Pollock RE, Weichselbaum RR et al editors. Holland - Frei Cancer Medicine. 6th edition. Hamilton(ON): BC Decker; 2003 (http://www.ncbi.nlm.nih.gov/books/NBK12718).
    36. Fludarabine phosphate. http://www.drugs.com/monograph/fludarabine-phosphate.html.
    37. Anonymous. Fludarabine. Preparation for iv injection. Prescrire Int 1996; 22: 44-46.
    38. Research Triangl Park; NC USA: 2005; Glaxo-SmithKline: Arranon (nelarabine) injection for intravenous use (product information).
    39. Roecker AM, Stockert A, Kisor DF. Neralabine in the treat-ment of refractory T-cell malignancies. Clin Med Insights Oncol 2010; 4: 133-141. Go to original source... Go to PubMed...
    40. Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006; 12: 5329-5335. Go to original source...
    41. Cooper TM. Role of neralabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag 2007; 3: 1135-1141.
    42. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004; 79: 927-930. Go to original source...
    43. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. http://www.fda.gov/downloads/DrugSafety/UCM365078.pdf.
    44. Sharafadinzadeh N, Moghtaderi A, Alavi-Naini R. Nitrofurantoin-induced peripheral neuropathy. A lesson to be learnt. Neurol India 2008; 56: 94-96. Go to original source... Go to PubMed...
    45. Takeuchi H, Takahashi M, Tarui S, Sanagi S, Takenaka H. Peripheral nerve conduction function in patients treated with antituberculotiic agents, with special reference to ethambutol and isoniazid. Psychiatry and Clinical Neurosciences 1980; 34: 57-64. Go to original source...
    46. McCarty M. How clinically relevant is dapsone - related peripheral neuropathy? An overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010; 3: 19-21.
    47. Didanosine. IARC Monographs volume 76. http://monographs.iarc.fr/ENG/Monographs/vol76/mono76-9.pdf.
    48. Scarsella A, Goodley G, Shalit P, et al. Stavudine-associated peripheral neuropathy in zidovudine-na?ve patients: effect of stavudine exposure and retroviral experience. Adv Ther 2002; 19: 1-8. Go to original source...
    49. Tableaux des principaux effects indésirables des antirétroviraux. Rev Prescrire 1999; 19: 894-897.
    50. Etravirine. http://aidsinfo.nih.gov/drugs/398/etravirine/O/professional.
    51. Peripheral neuropathy and statins. Prescrire Int 2007; 16: 247-248. Go to PubMed...
    52. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case control study. Neurology 2002; 58: 1333-1337. Go to original source... Go to PubMed...
    53. Otruba P, Kanovsky P, Hlustik P. Treatment with statins and peripheral neuropathy: results of 36-month a prospective clinical and neurophysiological follow-up. Neuro Endocrinol Lett 2011; 32: 688-690. Go to PubMed...
    54. Tierney EF, Thurman DJ, Beckles GL, Caldwell BL. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes 2013; 5: 207-215 doi: 10.1111/1753-0407.12013.
    55. Corrao G, Zambon A, Bertu L, Bpotteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. Epidemiol Community Health 2004; 58: 1047-1051. Go to original source...
    56. Malesker MA, Sojka SG, Fagan NL. Flecainide-induced neuropathy. Ann Pharmacother 2005; 39: 1580. Go to original source...
    57. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66: 865-869. Go to original source...
    58. Briani C, Zara G, Ruggero S, Negrin P. Disopyramide-induced neuropathy. J. Peripher Nerv Syst 2002; 7: 71-72. Go to original source...
    59. Polyneuropathy and visual disturbances on dronedarone (Multaq). Arznei-telegramm 2012; 43: 47.
    60. Tsujimoto G, Horai Y, Ishizaki T, Itoh K. Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient. Br J Clin Pharmacol 1981; 11: 622-625. Go to original source...
    61. Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology 2004; 43: 934. Go to original source...
    62. Metzler C, Arlt AC, Gross WL, Brandt J. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Dis 2005; 64: 1798-1800. Go to original source...
    63. Pool KD, Feit H, Kirkpatrick J. Penicilamine-induced neuropathy in rheumatoid arthritis. Ann Intern Med 1981; 95: 457-458. Go to original source...
    64. Weiss JJ, Thompson GR, Lazaro R. Gold toxicity presenting as peripheral neuropathy. Clin Rheumatol 1982; 1: 285-289. Go to original source... Go to PubMed...
    65. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927-2931. Go to PubMed...
    66. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occuring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 490-497. Go to original source... Go to PubMed...
    67. Hanaoka BY, Libecco J, Rensel M, Hajj-Ali RA. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol 2008; 35: 182-183. Go to PubMed...
    68. Rodrigues-Escalera C, Belzuneguil J, Lopez-Dominguez L, Gonzales C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology 2005; 44: 132-133. Go to original source...
    69. Azulay JP, Blin O, Valentin P, Abegg P, Pellissier JF, Serratrice G. Regression of allopurinol-induced peripheral neuropathy after drug withdrawal. Eur Neurol 1993; 33: 193-194. Go to original source...
    70. De Deyn PP, Ceuterick C, Saxena V, Crols R, Chappel R, Martin JJ. Chronic colchicine-induced myopathy and neuropathy. Acta Neurol Belg 1995; 95: 29-32. Go to PubMed...
    71. LeWitt PA, Forno LS. Peripheral neuropathy following amitriptyline overdose. Muscle Nerve 1985; 8: 723-724. Go to original source...
    72. Zampollo A, Sozzi G, Basso F. Amitriptyline-related neuropathy. Ital J Neurol 1988; 9: 89-91. Go to original source... Go to PubMed...
    73. Ramirez JA, Mendell JR, Warmolts JR, Griggs RC. Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol 1986; 19: 162-167. Go to original source... Go to PubMed...
    74. Dobkin BH. Reversible subacute peripheral neuropathy induced by phenytoin. JAMA Neurol 1977; 34: 189-190. Go to original source... Go to PubMed...
    75. Yoshikawa H, Abe T, Oda Y. Extremely acute phenytoin-induced peripheral neuropathy. Epilepsia 1999; 40: 528-529. Go to original source...
    76. Goodheart RS, Dunne JW, Edis RH. Phenelzine associated peripheral neuropathy-clinical and electrophysiological findings. Aust N Z J Med 1991; 21: 339-340. Go to original source... Go to PubMed...
    77. Heller CA, Friedman PA. Pyridoxine deficiency and peripheral neuropathy associated with long-term phenelzine therapy. Am J Med 1983; 75: 887-888. Go to original source...
    78. Labate A, Morelli M, Palamara G, Pirritano D, Quattrone A. Tacrolimus-induced polyneuropathy after heart transplantation. Clin Neuropharmacol 2010; 33: 161-162. Go to original source... Go to PubMed...
    79. De Weerdt A, Claeys KG, De Jongte P, et al. Tacrolimus-related polyneuropathy: Case report and review of the literature. Clin Neurol Neurosurg 2008; 110: 291-294. Go to original source... Go to PubMed...
    80. Bilodeau M, Hassoun Z, Brunet D. Demyelinating sensimotor polyneuropathy associated with the use of sirolimus: A case report. Transplant Proc 2008; 40: 1545-1547. Go to original source... Go to PubMed...
    81. Blin O, Desnuelle C, Pellissier JF, et al. Peripheral neuropathy and cyclosporin. Apropos of 2 cases. Therapie 1989; 44: 55-57. Go to PubMed...
    82. Sayin R, Soyoral YU, Erkoc R. Polyneuropathy due to cyclosporine A in patients with renal transplantation: a case report. Ren Fail 2011; 33: 528-530. Go to original source... Go to PubMed...
    83. Etemadi J, Shoja MM, Ghabili K, Telebi M, Namdar H, Mirnour R. Multiple etiologies of axonal sensory motor neuropathy in a renal transplant recipient: a case report. J Med Case Rep 2011; 5: 530. http://www.jmedicalcasereports.com/concent/5/1/530. Go to original source...
    84. Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010; 103: 265-267. Go to original source... Go to PubMed...
    85. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987: 76: 8-11. Go to original source... Go to PubMed...
    86. Clark RF, Strukle E, Williams SR, Manoguerra AS. Selenium poisoning from a nutritional supplement. JAMA 1996; 275: 1087-1088. Go to original source...
    87. Aldosary BM, Sutter ME, Schwartz M, Morgan BW. Case series of selenium toxicity from a nutritional supplement. Clin Toxicol(Phila) 2012; 50: 57-64. Go to original source... Go to PubMed...
    88. Nations SP, Boyer PJ, Love LA, et al. Denture cream. An unusual source of excess zinc, leading to hypocupremia and neurological disease. Neurology 2008; 71: 639-643. Go to original source... Go to PubMed...
    89. Anonymous. Surdoses de crémes adhésives dentaires: neuropathies. Rev Prescrire 2010; 30: 267.
    90. Gable KL, Afshari Z, Sufit RL, Allen JA. Distal acquired demyelinating symmetric neuropathy after vaccination. J Clin Neuromuscul Dis 2013; 14: 117-122. Go to original source... Go to PubMed...
    91. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillan-Barré syndrome. Drug Saf 2009; 32: 309-323. Go to original source...
    92. Nelson KE. Invited commentary: Influenza vaccine and Guillain-Barré syndrome: Is there a risk? Am J Epidemiol 2012; 175: 1129-1132. Go to original source...
    93. Mold JW, Vesely SK, Keyl BA, Schenk JB, Roberts MR. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004; 17: 309-318. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.